Integration of Metabolomics and Transcriptomics To Reveal Metabolic Characteristics and Key Targets Associated with Cisplatin Resistance in Nonsmall Cell Lung Cancer
Authors:
- 2 August 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 18 (9) , 3259-3267
Abstract
Continuous exposure to cisplatin can induce drug resistance to limit efficacy; however, the underlying mechanisms correlated with cisplatin resistance are still unclear. Drug-sensitive A549 cells and cisplatin-resistant A549/DDP cells were used to explore the potential metabolic pathways and key targets associated with cisplatin resistance by integrating untargeted metabolomics with transcriptomics. Data are available via ProteomeXchange with identifier PXD013265. The results of comprehensive analyses showed that 19 metabolites were significantly changed in A549/DDP versus A549 cells, and some pathways had a close relationship with cisplatin resistance, such as the biosynthesis of aminoacyl-tRNA, glycerophospholipid metabolism, and glutathione metabolism. Moreover, transcriptomics analysis showed that the glutathione metabolism was also obviously affected in A549/DDP, which indicated that the glutathione metabolism played an important role in the process of drug resistance. Meanwhile, transcriptomics analysis suggested the four enzymes related to glutathione metabolism—CD13, GPX4, RRM2B, and OPLAH—as potential targets of cisplatin resistance in nonsmall cell lung cancer. Further studies identified the overexpression of these four enzymes in A549/DDP. The elucidation of mechanism and discovery of new potential targets may help us have a better understanding of cisplatin resistance.Keywords
Funding Information
- Fund of Shanghai Pharmaceutical Association (2017-YY-02-11)
This publication has 37 references indexed in Scilit:
- Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer PatientsInternational Journal of Molecular Sciences, 2013
- 5-Oxoprolinuria in Heterozygous Patients for 5-Oxoprolinase (OPLAH) Missense Changes2012
- 5‐Oxoprolinase deficiency: report of the first human OPLAH mutationClinical Genetics, 2011
- CD13 is a therapeutic target in human liver cancer stem cellsJournal of Clinical Investigation, 2010
- The Sanger FASTQ file format for sequences with quality scores, and the Solexa/Illumina FASTQ variantsNucleic Acids Research, 2009
- Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesisInternational Journal of Cancer, 2005
- Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cellsCancer Letters, 2005
- Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic miceCancer Letters, 2004
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Leukemic Cell-Surface CD13/Aminopeptidase N and Resistance to Apoptosis Mediated by Endothelial CellsJNCI: Journal of the National Cancer Institute, 2002